(Health-NewsWire.Net, March 27, 2018 ) Publisher’s market research analyst predicts the global pharmerging markets to grow steadily at a CAGR of around 13% by 2021. One of the primary drivers for this market is the increasing focus toward biosimilar in potential areas. As most of the patents for originator biologics have expired, the vendors are focusing on the development of duplicate copies of biologics, called biosimilars. These biosimilars provide the same efficacy as that of parent molecule but at a cheaper cost. The availability of cheap manufacturing resources such as land and labor has made the pharmerging market an important option for the development of these biosimilars. For instance, in 2014 trastuzumab, (a biosimilar of CANMab), which is indicated for the treatment of metastatic breast cancer was launched in India. Moreover, the on-going strong market growth in therapeutic areas will contribute further to higher penetration of the pharmerging markets over the next few years.
One of the latest trends gaining traction in this market is the rise in the positive outlook through the adoption of targeted therapies. With the growing incidences of chronic diseases such as cancer, which requires specific therapies for effective treatment, the implementation of targeted therapies is expected to witness substantial upward momentum. Research studies have demonstrated that targeted therapy has increased the survival rate and the cure rate in cancer patients. These drugs are expected to work effectively in the treatment of various cancers such as lung cancer, breast cancer, chronic myeloid leukemia, and lymphomas. Moreover, the rising awareness among physicians about the advantages of targeted therapies will further enhance the adoption rates during the forecast period.
Sample Copy is Available @ http://www.reportsweb.com/inquiry&RW0001563243/sample
Competitive landscape and key vendors
The global pharmerging market is highly fragmented with the presence of a large number of local and international vendors distributed across the verticals. To gain a competitive advantage in this highly competitive market, the key players are moving toward consolidation, through acquisition and alliances; the competitive environment is expected to settle down at product innovation and launch level. Vendors that will offer customizable business model along with competitive pricing are also expected to grow during the forecast period.
Leading vendors in the market are -
AstraZeneca
GlaxoSmithKline
Pfizer
Sanofi
Novartis
Other prominent vendors in the pharmerging markets include Abbott Laboratories, AbbVie, Alexion Pharmaceuticals, Allergan, Amgen, Aspen, Astellas Pharma, Baxter, Bayer, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, CSL Behring, Daiichi Sankyo, Dainippon Sumitomo Pharma, Eisai, Eli Lilly, Endo Health Pharmaceuticals, F. Hoffmann-La Roche, Fresenius, Gilead, Grifols, H. Lundbeck, Hospira, Johnson & Johnson, Kyowa Hakko Kirin, Mallinckrodt Pharmaceuticals, Menarini, Mitsubishi Tanabe Pharma, Mylan, Novo Nordisk, Otsuka, Shire, STADA Arzneimittel, Sun Pharmaceutical, Takeda Pharma, Teva Pharmaceutical Industries, UCB, and Valeant Pharmaceuticals.
For Inquire before Buying @ http://www.reportsweb.com/inquiry&RW0001563243/buying
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Market Research Methodology
PART 04: Introduction
PART 05: Market landscape
PART 06: Five forces analysis
PART 07: Market segmentation
PART 08: Decision framework
PART 09: Drivers and challenges
PART 10: Market trends
Get Complete Report is Available at: http://www.reportsweb.com/global-pharmerging-markets-2017-2021
About Us:
ReportsWeb is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers.
Contact Us:
Phone: +1-646-491-9876 Email Id: sales@reportsweb.com
ReportsWeb.com
Rajat Sahni
6464919876
akash.kale@thensightpartners.com
Source: EmailWire.Com
|